Interpace Biosciences (STU:PF42) Cyclically Adjusted Revenue per Share: €12.44 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:PF42 Interpace Biosciences Inc STU:PF42
41 GF Score
Price €1.33
GF Value €0.17
! 5 Warning Signs
View Full Analysis

What is Interpace Biosciences Cyclically Adjusted Revenue per Share?

Interpace Biosciences STU:PF42 -0.75% 41 Cyclically Adjusted Revenue per Share is €12.44 as of Jun. 2026. GuruFocus rates STU:PF42 with a GF Score™ of 41/100 and a GF Value™ of €0.17. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Interpace Biosciences's adjusted revenue per share for the three months ended in Jun. 2026 was €0.286. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €12.44 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Interpace Biosciences's average Cyclically Adjusted Revenue Growth Rate was -37.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -49.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -48.40% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -33.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Interpace Biosciences was -0.40% per year. The lowest was -58.70% per year. And the median was -15.90% per year.

As of today (2026-08-21), Interpace Biosciences's current stock price is €1.33. Interpace Biosciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €12.44. Interpace Biosciences's Cyclically Adjusted PS Ratio of today is 0.11.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Interpace Biosciences was 0.19. The lowest was 0.01. And the median was 0.02.


Interpace Biosciences  (STU:PF42) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Interpace Biosciences's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1.33/12.44
=0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Interpace Biosciences was 0.19. The lowest was 0.01. And the median was 0.02.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Interpace Biosciences Cyclically Adjusted Revenue per Share Related Terms


Interpace Biosciences Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Interpace Biosciences's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Interpace Biosciences Cyclically Adjusted Revenue per Share Chart

Interpace Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 213.07 90.30 21.61 23.48 14.50

Interpace Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.76 16.04 14.50 11.89 12.44

STU:PF42 vs PRPO, ADVB, BIOQ: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, Interpace Biosciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Interpace Biosciences Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Interpace Biosciences's Cyclically Adjusted PS Ratio falls into.


STU:PF42
41GF Score
Interpace Biosciences Inc STU:PF42
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Interpace Biosciences Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Interpace Biosciences's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.286/333.9520*333.9520
=0.286

Current CPI (Jun. 2026) = 333.9520.

Interpace Biosciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 16.236 241.428 22.458
201612 15.914 241.432 22.012
201703 7.406 243.801 10.145
201706 3.552 244.955 4.843
201709 1.600 246.819 2.165
201712 1.327 246.524 1.798
201803 1.400 249.554 1.873
201806 1.686 251.989 2.234
201809 1.747 252.439 2.311
201812 1.791 251.233 2.381
201903 1.513 254.202 1.988
201906 1.455 256.143 1.897
201909 1.836 256.759 2.388
201912 0.990 256.974 1.287
202003 2.047 258.115 2.648
202006 1.199 257.797 1.553
202009 1.734 260.280 2.225
202012 1.962 260.474 2.515
202103 2.020 264.877 2.547
202106 2.257 271.696 2.774
202109 1.644 274.310 2.001
202112 1.928 278.802 2.309
202203 1.710 287.504 1.986
202206 1.654 296.311 1.864
202209 1.950 296.808 2.194
202212 1.841 296.797 2.071
202303 2.130 301.836 2.357
202306 2.358 305.109 2.581
202309 1.969 307.789 2.136
202312 2.110 306.746 2.297
202403 2.136 312.332 2.284
202406 2.542 314.175 2.702
202409 2.505 315.301 2.653
202412 2.688 315.605 2.844
202503 0.384 319.799 0.401
202506 1.810 322.561 1.874
202509 0.269 324.800 0.277
202512 0.284 324.054 0.293
202603 0.282 330.213 0.285
202606 0.286 333.952 0.286

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €12.44 mean?
Interpace Biosciences (STU:PF42) has a Cyclically Adjusted Revenue per Share of €12.44 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Interpace Biosciences and its competitors.
Is Interpace Biosciences' Cyclically Adjusted Revenue per Share too high?
Interpace Biosciences' current Cyclically Adjusted Revenue per Share is €12.44. Overall, Interpace Biosciences has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Interpace Biosciences' Cyclically Adjusted Revenue per Share compare to PRPO and ADVB?
Interpace Biosciences' Cyclically Adjusted Revenue per Share of €12.44 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Interpace Biosciences and its competitors. Interpace Biosciences's current Cyclically Adjusted Revenue per Share is €12.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Interpace Biosciences stock overvalued right now?
Interpace Biosciences (STU:PF42) has a current Cyclically Adjusted Revenue per Share of €12.44. The stock's GF Value™ is €0.17, compared to a current price of €1.33 — trading 682.4% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €12.44. Interpace Biosciences' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Interpace Biosciences (STU:PF42), the current Cyclically Adjusted Revenue per Share is €12.44 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Interpace Biosciences (STU:PF42) Overvalued in 2026?

Based on GuruFocus' analysis, Interpace Biosciences stock appears to be overvalued. The current stock price of €1.33 is trading 682.4% above its estimated GF Value™ of €0.17.

Key valuation signals for STU:PF42:

  • Cyclically Adjusted Revenue per Share: €12.44
  • GF Value™: €0.17 vs. price of €1.33 (682.4% above fair value)
  • GF Score™: 41/100 with 5 warning signs

No single metric tells the full story. See the STU:PF42 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Interpace Biosciences Business Description

Other Exchanges IDXG:USA
Address 2001 Route 46, Suite 310, Waterview Plaza, Parsippany, NJ, USA, 07054
Interpace Biosciences Inc provides esoteric molecular diagnostic testing and pathology services to aid physicians in evaluating cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer based on clinical features. The company develops and commercializes genomic tests and related first-line assays that can personalize medicine and help improve patient diagnosis and management. Its clinical customers mainly consist of physicians, hospitals, cancer centers, commercial laboratories, pathology groups, and clinics. The various diagnostic tests offered by the company include ThyGeNEXT and ThyraMIRv2 for the detection of thyroid cancer.
41GF Score

Get the complete analysis for STU:PF42

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.33
Price
€0.17
GF Value